Regen Biopharma Inc (RGBAD)

[dmort545]

Compound identified that appears to be effective in treating autoimmune diseases with almost no toxicity.Great News !!

https://finance.yahoo.com/news/regen-biopharma-inc-research-demonstrates-120000740.html

SAN DIEGO, July 25, 2017 /PRNewswire/ --

Regen BioPharma Inc. (RGBP) and (RGBPP) today reported continued progress in Regen's development of small molecule drugs that activate and inhibit NR2F6. The Company reports that recently identified novel chemical compounds that activate NR2F6 also selectively inhibit cytokines secreted from activated immune cells. This indicates that researchers have identified a compound that appears to be effective in treating autoimmune diseases with virtually no toxicity. Research was conducted by ChemDiv, Inc. (an internationally recognized contract research organization) which has been retained by Regen to conduct research and experiments on Regen's behalf.

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.